These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26880449)

  • 1. Eculizumab in children with hemolytic uremic syndrome.
    Kavanagh D; Smith-Jackson K
    Kidney Int; 2016 Mar; 89(3):537-8. PubMed ID: 26880449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.
    Baskin E; Gulleroglu K; Kantar A; Bayrakci U; Ozkaya O
    Pediatr Nephrol; 2015 May; 30(5):783-9. PubMed ID: 25384530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N; Ayer M; Ergen A; Ozturk S
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.
    Ferreira E; Oliveira N; Marques M; Francisco L; Santos A; Carreira A; Campos M
    Nefrologia; 2016; 36(1):72-5. PubMed ID: 26541438
    [No Abstract]   [Full Text] [Related]  

  • 12. ATYPICAL HEMOLYTIC UREMIC SYNDROME IN AN ADULT SUCCESSFULLY TREATED WITH ECULIZUMAB.
    Chaudoir C; Ong MG; Gu X; Veillon D; Cotelingam J
    J La State Med Soc; 2016; 168(1):12-5. PubMed ID: 26986861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.
    Salameh H; Abu Omar M; Alhariri A; Kisra S; Qasem A; Abdulhak AB
    Am J Ther; 2016; 23(4):e1110-5. PubMed ID: 25486517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
    Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.
    Zlamy M; Hofer J; Elias J; Vogel U; Frosch M; Jungraithmayr T; Zimmerhackl LB; Prelog M
    Pediatr Transplant; 2012 Sep; 16(6):E246-50. PubMed ID: 21967634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
    Loirat C; Fakhouri F; Ariceta G; Besbas N; Bitzan M; Bjerre A; Coppo R; Emma F; Johnson S; Karpman D; Landau D; Langman CB; Lapeyraque AL; Licht C; Nester C; Pecoraro C; Riedl M; van de Kar NC; Van de Walle J; Vivarelli M; Frémeaux-Bacchi V;
    Pediatr Nephrol; 2016 Jan; 31(1):15-39. PubMed ID: 25859752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
    Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
    Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.
    Keenswijk W; Raes A; Vande Walle J
    Eur J Pediatr; 2018 Mar; 177(3):311-318. PubMed ID: 29288280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.